FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2574064190> ?p ?o ?g. }

• W2574064190 endingPage "150" @default.
• W2574064190 startingPage "150" @default.
• W2574064190 abstract "150 Background: Zoledronic acid (ZA) is proved to be useful for the prevention of skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases, but its early use combined with androgen deprivation therapy (ADT) in men with hormonal treatment-naïve prostate cancer and bone metastases is controversial. Methods: A total of 227 men with hormonal treatment-naïve prostate cancer and bone metastases were randomly assigned in a 1:1 ratio to receive zoledronic acid (4mg intravenously every 4 weeks up to 2 years) along with ADT (LH-RH analogue + bicalutamide, MZ group) or ADT alone (MAB group). Stratification factors were PSA (<200ng/ml vs. ≥200ng/ml), EOD (extent of diseases) grade (1,2 vs. 3,4) and Gleason score (<7 vs. ≥8). The primary end point was time to treatment failure (TTTF), defined as 3 consecutive rise of PSA from the nadir, clinical progression, SRE, death or cessation of protocol therapy for any reason. Results: The median follow-up was 41.1 months. The median TTTF was 12.4 months in MZ group (95% CI, 10.6 to 16.6) and 9.7 months in MAB group (95% CI, 8.9 to 12.6; hazard ratio, 0.754; 95% CI, 0.567 to 1.003; log-rank P= .051). In a subset of men with baseline PSA levels <200ng/mL, the median TTTF was 23.7 months in MZ group (95% CI, 15.2 to 31.3) and 9.8 months in MAB group (95% CI, 6.6 to 17.0; hazard ratio, 0.575; 95% CI, 0.354 to 0.933; log-rank P= .023). An exploratory multivariate analysis using Cox proportional hazards model identified MZ group, age less than 80, and EOD ≤2 as independent factors associated with better TTTF. Conclusions: In men with hormonal treatment naïve prostate cancer with bone metastases, concurrent use of ZA with ADT did not show a significant advantage over ADT alone regarding TTTF. However, in a subgroup of men with lower baseline PSA levels, ZA significantly prolonged TTTF, compared with ADT alone. Clinical trial information: NCT00685646." @default.
• W2574064190 created "2017-01-26" @default.
• W2574064190 creator A5004686294 @default.
• W2574064190 creator A5004702538 @default.
• W2574064190 creator A5005819073 @default.
• W2574064190 creator A5009433306 @default.
• W2574064190 creator A5013917805 @default.
• W2574064190 creator A5016304390 @default.
• W2574064190 creator A5017624165 @default.
• W2574064190 creator A5039271211 @default.
• W2574064190 creator A5046195007 @default.
• W2574064190 creator A5047951647 @default.
• W2574064190 creator A5075102109 @default.
• W2574064190 creator A5077840773 @default.
• W2574064190 creator A5078394115 @default.
• W2574064190 creator A5079627883 @default.
• W2574064190 creator A5083025134 @default.
• W2574064190 creator A5083918280 @default.
• W2574064190 creator A5086586078 @default.
• W2574064190 creator A5089041550 @default.
• W2574064190 date "2015-03-01" @default.
• W2574064190 modified "2023-10-16" @default.
• W2574064190 title "A phase III, multicenter, randomized, controlled study of maximum androgen blockade with versus without zoledronic acid in treatment-naïve prostate cancer patients with bone metastases: Results of ZAPCA study." @default.
• W2574064190 doi "https://doi.org/10.1200/jco.2015.33.7_suppl.150" @default.
• W2574064190 hasPublicationYear "2015" @default.
• W2574064190 type Work @default.
• W2574064190 sameAs 2574064190 @default.
• W2574064190 citedByCount "3" @default.
• W2574064190 countsByYear W25740641902017 @default.
• W2574064190 countsByYear W25740641902018 @default.
• W2574064190 countsByYear W25740641902020 @default.
• W2574064190 crossrefType "journal-article" @default.
• W2574064190 hasAuthorship W2574064190A5004686294 @default.
• W2574064190 hasAuthorship W2574064190A5004702538 @default.
• W2574064190 hasAuthorship W2574064190A5005819073 @default.
• W2574064190 hasAuthorship W2574064190A5009433306 @default.
• W2574064190 hasAuthorship W2574064190A5013917805 @default.
• W2574064190 hasAuthorship W2574064190A5016304390 @default.
• W2574064190 hasAuthorship W2574064190A5017624165 @default.
• W2574064190 hasAuthorship W2574064190A5039271211 @default.
• W2574064190 hasAuthorship W2574064190A5046195007 @default.
• W2574064190 hasAuthorship W2574064190A5047951647 @default.
• W2574064190 hasAuthorship W2574064190A5075102109 @default.
• W2574064190 hasAuthorship W2574064190A5077840773 @default.
• W2574064190 hasAuthorship W2574064190A5078394115 @default.
• W2574064190 hasAuthorship W2574064190A5079627883 @default.
• W2574064190 hasAuthorship W2574064190A5083025134 @default.
• W2574064190 hasAuthorship W2574064190A5083918280 @default.
• W2574064190 hasAuthorship W2574064190A5086586078 @default.
• W2574064190 hasAuthorship W2574064190A5089041550 @default.
• W2574064190 hasConcept C121608353 @default.
• W2574064190 hasConcept C126322002 @default.
• W2574064190 hasConcept C126894567 @default.
• W2574064190 hasConcept C143998085 @default.
• W2574064190 hasConcept C168563851 @default.
• W2574064190 hasConcept C203092338 @default.
• W2574064190 hasConcept C207103383 @default.
• W2574064190 hasConcept C2776326535 @default.
• W2574064190 hasConcept C2777899217 @default.
• W2574064190 hasConcept C2777911890 @default.
• W2574064190 hasConcept C2778311097 @default.
• W2574064190 hasConcept C2780192828 @default.
• W2574064190 hasConcept C44249647 @default.
• W2574064190 hasConcept C71315377 @default.
• W2574064190 hasConcept C71924100 @default.
• W2574064190 hasConceptScore W2574064190C121608353 @default.
• W2574064190 hasConceptScore W2574064190C126322002 @default.
• W2574064190 hasConceptScore W2574064190C126894567 @default.
• W2574064190 hasConceptScore W2574064190C143998085 @default.
• W2574064190 hasConceptScore W2574064190C168563851 @default.
• W2574064190 hasConceptScore W2574064190C203092338 @default.
• W2574064190 hasConceptScore W2574064190C207103383 @default.
• W2574064190 hasConceptScore W2574064190C2776326535 @default.
• W2574064190 hasConceptScore W2574064190C2777899217 @default.
• W2574064190 hasConceptScore W2574064190C2777911890 @default.
• W2574064190 hasConceptScore W2574064190C2778311097 @default.
• W2574064190 hasConceptScore W2574064190C2780192828 @default.
• W2574064190 hasConceptScore W2574064190C44249647 @default.
• W2574064190 hasConceptScore W2574064190C71315377 @default.
• W2574064190 hasConceptScore W2574064190C71924100 @default.
• W2574064190 hasIssue "7_suppl" @default.
• W2574064190 hasLocation W25740641901 @default.
• W2574064190 hasOpenAccess W2574064190 @default.
• W2574064190 hasPrimaryLocation W25740641901 @default.
• W2574064190 hasRelatedWork W1988873325 @default.
• W2574064190 hasRelatedWork W2003982473 @default.
• W2574064190 hasRelatedWork W2009831081 @default.
• W2574064190 hasRelatedWork W2059391072 @default.
• W2574064190 hasRelatedWork W2127440557 @default.
• W2574064190 hasRelatedWork W2140675573 @default.
• W2574064190 hasRelatedWork W2162051638 @default.
• W2574064190 hasRelatedWork W2234129137 @default.
• W2574064190 hasRelatedWork W56999985 @default.
• W2574064190 hasRelatedWork W2595609823 @default.
• W2574064190 hasVolume "33" @default.
• W2574064190 isParatext "false" @default.
• W2574064190 isRetracted "false" @default.
• W2574064190 magId "2574064190" @default.

• next